Ultragenyx Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RARE and other ETFs, options, and stocks.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. 

CEO
Emil D. Kakkis
CEOEmil D. Kakkis
Employees
1,294
Employees1,294
Headquarters
Novato, California
HeadquartersNovato, California
Founded
2010
Founded2010
Employees
1,294
Employees1,294

RARE Key Statistics

Market cap
2.22B
Market cap2.22B
Price-Earnings ratio
-3.87
Price-Earnings ratio-3.87
Dividend yield
Dividend yield
Average volume
4.67M
Average volume4.67M
High today
$23.25
High today$23.25
Low today
$21.90
Low today$21.90
Open price
$22.55
Open price$22.55
Volume
3.67M
Volume3.67M
52 Week high
$46.50
52 Week high$46.50
52 Week low
$18.41
52 Week low$18.41

Stock Snapshot

With a market cap of 2.22B, Ultragenyx Pharmaceutical(RARE) trades at $23.00. The stock has a price-to-earnings ratio of -3.87.

On 2026-01-02, Ultragenyx Pharmaceutical(RARE) stock traded between a low of $21.90 and a high of $23.25. Shares are currently priced at $23.00, which is +5.0% above the low and -1.1% below the high.

Ultragenyx Pharmaceutical(RARE) shares are trading with a volume of 3.67M, against a daily average of 4.67M.

During the past year, Ultragenyx Pharmaceutical(RARE) stock moved between $18.41 at its lowest and $46.50 at its peak.

During the past year, Ultragenyx Pharmaceutical(RARE) stock moved between $18.41 at its lowest and $46.50 at its peak.

RARE News

The Motley Fool 3d
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today

One analyst sees significant upside for the stock after yesterday's sell-off. While Ultragenyx Pharmaceutical (RARE +15.52%) provided the market with disappoin...

Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
Benzinga 3d
Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares plunged 42% on Monday after the company and partner Mereo BioPharma Group plc (NASDAQ:MREO) disclosed disapp...

Benzinga 4d
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) stocks hit their 52-week low on Monday, as per data from Benzinga Pro....

Analyst ratings

95%

of 22 ratings
Buy
95.5%
Hold
4.5%
Sell
0%

People also own

Based on the portfolios of people who own RARE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.